



## LI Renjiu(John)

Senior Joint Partner

Offices Beijing

Phone 13651147265

Email [lirenjiu@deheng.com](mailto:lirenjiu@deheng.com)

Language 中文, 英文

---

Practices Intellectual Property Business Center

---

### Social Positions

National Advisory Expert for Overseas Intellectual Property Dispute Settlement

Evaluation Expert for National Committee on the Assessment of the Protected Traditional Chinese Medicinal Products.

Cooperative Supervisor for Master ' s Students at Zhongnan University of Economics and Law.

Director of the Beijing Patent Attorneys Association.

### Education

Senior Visiting Scholar, Cardozo Law School in New York City, USA, Jul. – Dec. 2009.

M.S, Natural Medicine Chemistry, China-Japan Friendship Clinical Institute, 1995-1998.

B.A., Pharmaceutical Chemistry, Peking University, 1991-1995.

## Practice Experience

1998-2002, Patent Examiner, Pharmaceutical and Biotechnology Invention Examination Department of China National Intellectual Property Administration (CNIPA).

2003-2017, Public Lawyer and Director of Pharmaceutical Appeal Division, Patent Reexamination and Invalidation Department of China National Intellectual Property Administration (CNIPA).

2006, People ' s Juror, Beijing First Intermediate Court (detachment).

2017-2021, Senior Patent Director, Luye Pharm Group, a well-known pharmaceutical company in China.

2021-Present, Senior Partner, Beijing DHH Law Firm.

## Representative matters

1. Mr. Li Renjiu has worked at China National Intellectual Property Administration (CNIPA) for nearly 20 years. He served as director and public lawyer, and was recognized as a high-level talent by the National Intellectual Property Administration (2009). Mr. Li Renjiu has participated in thousands of patent examination, review, invalidation and litigation cases. He was also seconded to the Beijing First Intermediate Court for one year, where he took part in dozens of patent civil cases, as well as cases involving trademarks, trade secrets, technology contracts and copyrights as a People ' s Juror.

2. During his work in Luye Pharm Group, he was responsible for FTO analysis, patent due diligence and patent dispute resolution. He represented the company in several patent dispute cases and achieved success, including patent administrative and civil litigation in China, IPR and ANDA litigation in the US, patent opposition in the EPO, and patent invalidation in Germany.

## Representative matters (Part I, in IP legal Services for Pre-IPO Companies)

1. Intellectual property legal Services for pre-IPO companies, such as Beijing Yimiao Shenzhou Pharmaceutical Technology Co., Ltd., Beijing Darwin Cell Biology Technology Co., Ltd. , and Hebei Lansheng Biotechnology Co., Ltd.

## Representative matters (Part II, in Domestic Patent Disputes)

1. In the first instance administrative case of Traditional Chinese Medicine Patent Invalidation, as a public lawyer of CNIPA, Mr. Li Renjiu expressed why the term “ be made of. . . . . ” is an open-ended term rather than a close-ended term, and the courts of the first and second instance accepted the opinion.

2. Represented Shandong Luye Pharm Co. Ltd., Patent Infringement Case in China , (2016)Hu73Ming Chu581 , Patent Publication No.CN1271401C , we prevailed.

3. Represented Shandong Luye Pharm Co. Ltd., Patent Invalidation Case in China, Decision No.37390, Patent Publication No. CN1195505C (WO2001/011967A2), we withdraw the invalidation petition due to amendment of the claims.

4. Represented Luye Pharm. Group in a patent infringement case involving a certain experimental instrument.

5. Represented Shanghai Fosun Star Pharmaceutical Co., Ltd. of Fosun Pharmaceutical Group in the second instance of administrative litigation for invalidation of a patent of a Japanese company.

6. Represented Shanghai Ellis Pharmaceutical Co., Ltd. in the invalidation case of an anti-tumor drug patent of a domestic company.

7. Represented Novo Nordisk in the invalidation case of an anti-diabetic patent.

8. Represented AstraZeneca in the invalidation case of the Andatan series patents.

9. Represented Chongqing YaoPharma Pharmaceutical Co., Ltd. in a civil litigation case of patent dispute over drug registration.

10. Represented Jiangxi Qingfeng Pharmaceutical Group in a civil litigation case of patent dispute over drug registration.

11. Represented Jinfar Technology Group in the invalidation case of biodegradable polyester series patents.

## Representative matters (Part III, in Foreign Patent Disputes)

1. Served Luye Pharm. Group in a IPR procedure for US patents against Johnson & Johnson.

2.Served Nanjing Luye Pharm Co. Ltd., as opponent in the EPO Opposition Case of EP2269577B1, we prevailed because OD revoked the patent.

3.Served Shandong Luye Pharm Co. Ltd., as Patentee in EPO Opposition Case of EP2701687B1, we prevailed both in the Opposition and Appeal Procedure.

4.Served Shandong Luye Pharm Co. Ltd., as Patentee, EPO Opposition Case, Patent No. EP3199146B, we prevailed in the Opposition.

5.Served Luye Pharm.Group in U.S ANDA Case., No. C.A. No.: 1:19-cv-01340-LPS Patent No. US6,667,071 B2, the case was dismissed because of the settlement between both sides.

#### Representative matters (Part

1.Participated in China Resources Life Science Group and a medical machinery company investment and acquisition project.

2.Participated in Luye Pharm. Group and US Alkemes/Johnson & Johnson patent settlement agreement project.

3.Participated in a domestic pharmaceutical company and a US company patent licensing and technology transfer project.

4.Participated in a domestic pharmaceutical group and a European company patent licensing project.

5.Participated in a domestic battery material listed company and a European enterprise patent licensing project.

6.Participated in Shanghai Ellis Pharmaceutical Co., Ltd. and Shanghai Pharmaceutical Research Co., Ltd. patent transfer project for an anti-tumor drug.

7.Participated in Shanghai Anyuan Pharmaceutical Technology Co., Ltd. and a domestic pharmaceutical group peptide technology licensing and transfer agreement project.

8.Participated in Shanghai investment company investing in a biotechnology company intellectual property due diligence project.

#### Publications and Research Projects

1. Discussion on the Impact of Patent Invalidation Decisions on Patent Linkage Litigation, Intellectual Property Frontier, February 9, 2023.
2. Discussion on the Grant, Confirmation and Infringement of Prodrug and Metabolite Patents, Intellectual Property Force, October 27, 2022.
3. The Major Special Research Project of the State Intellectual Property Office "Research on Patent Confirmation and Administrative Adjudication under the Drug Patent Link System", Project number ZX202002, May-November 2020
4. "How to Understand Pharmaceutical Use Claims", China Intellectual Property News", 2016. 12.16
5. "Analysis of Typical Cases of Reexamination and Invalidation in the Field of Medicine and Biology", Intellectual Property Press, 2015.1.
6. "Analysis of Typical Cases of Pharmaceutical Patent Protection", Intellectual Property Press, 2012.10.
7. "Patent Reexamination Board Case Interpretation-Other Substantive Conditions for Patent ", Intellectual Property Press, 2011.9
8. "Examination Practice of the EPO on Surgical Treatment Methods-Analysis of Decision G1/07 of the EPO Expansion Appeals Board", China Inventions and Patents, vol 5 , 2012.
9. "Research on the Development Trend of Patented Technology in the Field of Biological Vaccines at Home and Abroad ", China Medical Biotechnology, Vol6, 2011
10. "How to consider the Publicity of Drug Standards Evidence in the Patent Practice", Intellectual Property, vol.2 2006

#### Awards

Recognized as a high-level talent by the National Intellectual Property Administration (2009).